Huakang Biomedical Holdings Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Chunguang Zhang

Geschäftsführender

CN¥703.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	44.7%
Amtszeit als Geschäftsführer	6.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.4yrs

Jüngste Management Updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chunguang Zhang im Vergleich zu den Einnahmen von Huakang Biomedical Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	CN¥703k	CN¥314k	-CN¥6m
Sep 30 2023	n/a	n/a	-CN¥5m
Jun 30 2023	n/a	n/a	-CN¥4m
Mar 31 2023	n/a	n/a	-CN¥3m
Dec 31 2022	CN¥689k	CN¥308k	-CN¥3m
Sep 30 2022	n/a	n/a	-CN¥2m
Jun 30 2022	n/a	n/a	-CN¥3m
Mar 31 2022	n/a	n/a	-CN¥4m
Dec 31 2021	CN¥399k	CN¥271k	-CN¥4m
Sep 30 2021	n/a	n/a	-CN¥7m
Jun 30 2021	n/a	n/a	-CN¥8m
Mar 31 2021	n/a	n/a	-CN¥10m
Dec 31 2020	CN¥727k	CN¥250k	-CN¥12m
Sep 30 2020	n/a	n/a	-CN¥9m
Jun 30 2020	n/a	n/a	-CN¥7m
Mar 31 2020	n/a	n/a	-CN¥3m
Dec 31 2019	CN¥349k	CN¥227k	-CN¥284k
Sep 30 2019	n/a	n/a	-CN¥3m
Jun 30 2019	n/a	n/a	-CN¥2m
Mar 31 2019	n/a	n/a	-CN¥377k
Dec 31 2018	CN¥284k	CN¥234k	-CN¥459k
Dec 31 2017	CN¥243k	CN¥183k	-CN¥2m

Vergütung im Vergleich zum Markt: ChunguangDie Gesamtvergütung ($USD96.87K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD233.22K).

Entschädigung vs. Einkommen: ChunguangDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Chunguang Zhang (56 yo)

6.8yrs

Amtszeit

CN¥703,000

Vergütung

Mr. Chunguang Zhang is Chief Executive officer at Huakang Biomedical Holdings Company Limited. Mr. Zhang is mainly responsible for business operations and the day-to-day management of Group. Mr. Zhang has...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shuguang Zhang	Chairman of the Board	6.8yrs	CN¥479.00k	27.71% CN¥ 13.5m
Chunguang Zhang	CEO & Executive Director	6.8yrs	CN¥703.00k	keine Daten
Lai Yin Poon	CFO, Compliance Officer & Executive Director	6.8yrs	CN¥769.00k	0.80% CN¥ 388.0k
Jiaming He	Business Development Director & Executive Director	4.4yrs	CN¥484.00k	keine Daten
Faat Ting Cheng	Independent Non Executive Director	3.8yrs	CN¥90.00k	keine Daten
Yim Yang Chang	Vice Chairman of King Grace Company Limited	no data	keine Daten	0% CN¥ 0
Kwok Fai Chow	Independent Non-Executive Director	3.5yrs	CN¥90.00k	keine Daten
Ching Man Chow	Independent Non-Executive Director	less than a year	CN¥38.00k	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrener Vorstand: 8622Die Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).

Huakang Biomedical Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Chairman of the Board recently sold HK$815k worth of stock

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Recent updates

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter